Evidence map›Paper›PMID 39995876›Full record

ArticleiScience2025

ENTPD8 overexpression enhances anti-PD-L1 therapy in hepatocellular carcinoma via miR-214-5p inhibition.

Si-Qi Zhao, Min-Jie Chen, Fei Chen, Zhao-Feng Gao, Xiao-Ping Li, Ling-Yu Hu, Hai-Ying Cheng, Jin-Yan Xuan, Jian-Guo Fei, Zheng-Wei Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Si-Qi ZhaoDepartment of Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Min-Jie ChenDepartment of Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Fei ChenDepartment of Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Zhao-Feng GaoDepartment of Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Xiao-Ping LiDepartment of Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Ling-Yu HuDepartment of Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Hai-Ying ChengDepartment of Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Jin-Yan XuanDepartment of General Practice, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Jian-Guo FeiDepartment of Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Zheng-Wei SongDepartment of Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with poor prognosis due to late diagnosis and limited treatment options. In this study, we evaluated the expression of ectonucleoside triphosphate diphosphohydrolase 8 (ENTPD8) in HCC tissues and its clinical significance. Immunohistochemistry, The Cancer Genome Atlas (TCGA) data, and single-cell expression analysis revealed reduced ENTPD8 levels in liver cancer compared to adjacent tissues, with ENTPD8 primarily expressed in tumor cells within the tumor tissue.

Indexed as

cancercell biologymolecular biology

Identifiers

PMID39995876
PMCPMC11849663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.